Key result
Viabahn VBX covered stent linked to ~6-point higher 5-year freedom from TLR in aortoiliac disease.
Why the study?
The Viabahn VBX balloon-expandable covered stent is designed for complex aorto-iliac lesions, but knowledge on its long-term durability compared with a bare-nitinol stent in endovascular treatment was limited.
Does a balloon-expandable covered stent (Viabahn VBX) improve 5-year freedom from target lesion revascularization compared to a bare-nitinol stent in patients undergoing endovascular treatment for aorto-iliac lesions?
Cohort (n=438)
Yes
Does a balloon-expandable covered stent (Viabahn VBX) improve 5-year freedom from target lesion revascularization compared to a bare-nitinol stent in patients undergoing endovascular treatment for aorto-iliac lesions?
In patients undergoing endovascular treatment for aorto-iliac lesions, the balloon-expandable covered stent (Viabahn VBX) demonstrated superior 5-year freedom from target lesion revascularization compared to bare-nitinol stents, particularly in TASC II C/D and severely calcified lesions.
Answers are grounded in this paper and cite their sources.
Medium-term patency in complex calcified AI lesions supports VBX consideration; leaves open randomized comparison to bare-nitinol stents.
Background Endovascular treatment (EVT) for aorto-iliac (AI) lesions is widely performed, and guidelines recommend use of a bare-nitinol stent (BNS) or covered stent (CS). A CS is particularly recommended for complex and severely calcified lesions. The Viabahn VBX (W.L. Gore & Associates, Flagstaff, AZ) is a balloon-expandable CS designed for use in complex AI lesions. However, there is limited knowledge on long-term durability compared with a BNS. The aim of this study is to evaluate long-term outcomes in patients undergoing AI EVT with Viabahn VBX. Methods A retrospective, multicenter study was performed to compare outcomes in patients undergoing AI EVT using Viabahn VBX with those using a BNS. Results The subjects were 438 consecutive patients (551 limbs) who underwent AI EVT using Viabahn VBX (137 patients, 187 limbs) or a BNS (301 patients, 364 limbs) from 2018 to 2020 at nine vascular centers. 5-year freedom from target lesion revascularization (TLR) was significantly higher in the Viabahn VBX group compared to the BNS group (94.4% (95% CI 88.4-97.4%) vs. 88.6% (83.7-92.1%), P = .028). Viabahn VBX use was significantly associated with improved freedom from TLR after adjustment for lesion characteristics and procedural details. In patients with TASC II C or D lesions or severe calcification (360°), Viabahn VBX gave higher freedom from TLR ( P = .003, P < .001) and better primary patency ( P = .044, P = .003) than BNS. 5-year limb salvage, freedom from major adverse limb events, and survival rates did not differ significantly between the groups. Conclusions Viabahn VBX showed higher long-term freedom from TLR compared with BNS in patients undergoing AI intervention. Further investigation is needed for an appropriate device (Viabahn VBX or BNS) in patients with AI occlusive lesion.
No takes yet. Share an insight, caveat, or question.
Maeda et al. (2026) conducted a cohort in Aortoiliac occlusive lesions (n=438). Viabahn VBX balloon-expandable covered stent vs. Bare-nitinol stent (BNS) was evaluated on 5-year freedom from target lesion revascularization (TLR) (p=0.028). Viabahn VBX covered stent yielded higher 5-year freedom from target lesion revascularization than bare-nitinol stents in aortoiliac interventions.
Synapse has enriched 10 related papers. Consider them for comparative context: